Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Oct 13 · below the Ichimoku cloud · RSI 36 · MACD below its signal
None of the 29 investors followed here reported a position in 9688.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 9688.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 11, 2026 | Lis (William David)Independent Non-Executive Director | Sale at price 0.32 per share. | 85.1K | $27.12K |
| Jul 1, 2026 | Du (Ying Samantha)Chief Executive Officer | — | 110.5K | — |
| Jul 1, 2026 | Du (Ying Samantha)Chief Executive Officer | Sale at price 0.24 per share. | 43.5K | $10.60K |
| Jun 30, 2026 | Du (Ying Samantha)Chief Executive Officer | — | 259.7K | — |
| Jun 30, 2026 | Du (Ying Samantha)Chief Executive Officer | Sale at price 0.24 per share. | 70.8K | $17.29K |
| Jun 30, 2026 | Gaynor (Richard Brian M.D.)Independent Non-Executive Director | Acquisition at price 1.90 per share. | 17.4K | $33.07K |
| Jun 29, 2026 | Du (Ying Samantha)Chief Executive Officer | Sale at price 1.85 per share. | 70.3K | $130.22K |
| Jun 28, 2026 | Du (Ying Samantha)Chief Executive Officer | — | 100K | — |
| Jun 25, 2026 | Du (Ying Samantha)Chief Executive Officer | — | 245.4K | — |
| Jun 24, 2026 | Du (Ying Samantha)Chief Executive Officer | — | 588K | — |
| Jun 21, 2026 | Lis (William David)Independent Non-Executive Director | Sale at price 0.23 per share. | 70.4K | $16.24K |
| May 26, 2026 | Du (Ying Samantha)Chief Executive Officer | — | 878.4K | — |
| May 25, 2026 | Du (Ying Samantha)Chief Executive Officer | — | 198.6K | — |
| May 18, 2026 | Du (Ying Samantha)Chief Executive Officer | — | 2.61M | — |
| May 18, 2026 | Du (Ying Samantha)Chief Executive Officer | Sale at price 0.24 per share. | 1.17M | $281.02K |
| Apr 5, 2026 | Du (Ying Samantha)Chief Executive Officer | Sale at price 0.26 per share. | 26.5K | $6.92K |
| Apr 1, 2026 | Du (Ying Samantha)Chief Executive Officer | — | 67.5K | — |
| Apr 1, 2026 | Du (Ying Samantha)Chief Executive Officer | Sale at price 0.26 per share. | 55.8K | $14.50K |
| Mar 31, 2026 | Du (Ying Samantha)Chief Executive Officer | — | 142K | — |
| Mar 16, 2026 | Gaynor (Richard Brian M.D.)Independent Non-Executive Director | Acquisition at price 1.89 per share. | 17.3K | $32.73K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.5 | 14.7 | -9.0 | 20.2 | -15.5 | 4.0 | -1.1 | 38.5 | 4.2 | -15.3 | +28.4% | ||
| 2025 | -0.5 | 27.3 | 7.1 | -14.0 | -1.8 | 14.1 | 6.9 | -12.7 | 4.1 | -24.7 | -21.3 | -14.0 | −35.2% |
| 2024 | -21.7 | 1.2 | -24.3 | 0.8 | 12.6 | -8.5 | 11.2 | 2.3 | 24.8 | 25.7 | -6.1 | -6.5 | −2.3% |
| 2023 | 31.3 | -13.0 | -7.3 | 4.6 | -5.1 | -18.8 | 17.4 | -15.0 | -9.6 | 4.8 | 7.1 | 1.2 | −12.6% |
| 2022 | -32.1 | 18.8 | -12.0 | -8.3 | -24.4 | 7.4 | 19.8 | 10.6 | -22.7 | -34.0 | 50.4 | -9.6 | −51.4% |
| 2021 | 15.6 | -7.4 | -7.1 | 25.8 | 6.7 | -1.2 | -22.4 | 4.0 | -23.7 | -3.2 | -30.8 | -10.0 | −51.1% |
| 2020 | 0.6 | 29.0 | 24.4 | +61.5% |
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Buy / hold / sell counts
No recent headlines.